The Company is now in cash conservation mode evidenced by the apparent pulling of open positions and cancellation of the chemo trials. Unfortunately, for the employees, there will probably be a restructuring announced with the CC. We all lose in this deal until the ship is righted-which it can be. So no obligation whatsoever to support the SP (although Noble may be attempting to stabilize) by Peregrine. I'm not convinced there is a wall or lid. Look at other trials for small biotechs. Big hit, then they usually equilibrate. Unless there is a Shkreli-but he is busy dropping $10M on Kanye.
Market Data 
Markets 
AI
